Premium
bcl‐2 inhibits mitochondrial metabolism and lonidamine‐induced apoptosis in adriamycin‐resistant mcf7 cells
Author(s) -
Biroccio Annamaria,
Del Bufalo Donatella,
Fanciulli Maurizio,
Bruno Tiziana,
Zupi Gabriella,
Floridi Aristide
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19990702)82:1<125::aid-ijc21>3.0.co;2-q
Subject(s) - apoptosis , cell culture , metabolism , cancer research , biology , cancer cell , oxidative phosphorylation , chemistry , cancer , endocrinology , biochemistry , genetics
Lonidamine (LND), a selective inhibitor of the energy metabolism of tumor cells, induces apoptosis, independently of the p53 gene, in the adriamycin(ADR)‐resistant MCF7 breast‐cancer cell line (MCF7 ADR). On the contrary, LND fails to activate the apoptotic program in the parental MCF7‐sensitive cell line (MCF7 WT). The extent of bcl‐2 expression might account for the different effect of LND on these cell lines. In fact, the MCF7 ADR line shows a low level of bcl‐2 protein, whereas MCF7 WT expresses a high level of bcl‐2. We therefore investigated the relationship between the amount of bcl‐2 and the ability of LND to induce apoptosis, using 4 clones over‐expressing bcl‐2. The effect of bcl‐2 on the energy metabolism was also evaluated. We demonstrated that over‐expression of bcl‐2 inhibited LND‐induced apoptosis, while reducing 14 CO 2 production, oxygen uptake and ATP content, whereas aerobic lactate production was essentially unaffected. In addition, LND decreased the oxidative metabolism of the MCF7 ADR cells to a greater extent than it did in the bcl‐2 transfectants. Int. J. Cancer 82:125–130, 1999. © 1999 Wiley‐Liss, Inc.